Neovasc said it had resolved the three claims of correction of patent inventorship made by Irvine, CA-based Edwards Lifesciences.
The Lake Oswego, OR-based company received a nod from FDA for the coronary stent system in September of 2018 but launched the device this month to coincide with the release of Orsiro, its ultrathin strut DES.
The Rolling Stones frontman’s recent procedure has brought a great deal of awareness to the TAVR market, which could be beneficial to device makers in the space.
Silk Road Medical CEO Erica Rogers performed one of her legendary cartwheels Thursday during the company's closing bell ceremony. The company's IPO shot up 81% on its opening day, raising $120 million.
The Marlborough, MA-based company has secured CE mark for its HeartLight X3 and said it has seen triple-digit growth for its atrial fibrillation treatment technologies.
Impulse Dynamics, one of 16 private companies Canaccord Genuity named ‘promising’ in a January analyst report, has received approval for the Optimizer Smart System.
Researchers at Rochester Institute of Technology have created a toilet seat that detects congestive heart failure.
The Cupertino, CA-based company released preliminary data from the Apple Heart Study, which demonstrates the effectiveness of wearables to detect atrial fibrillation.
R-One is the first European robotic solution to obtain the CE mark in the field of interventional cardiology.
The Abbott Park, IL-based company’s expanded indication would allow the MitraClip to address the secondary form of mitral regurgitation and would significantly increase the amount of people with MR able to be treated by the device.
Watchman has been a significant driver for Boston Scientific and is expected to have strong growth this year as well.
A medtech analyst says recent developments have created more uncertainty about paclitaxel-coated balloons and stents.
As the Irvine, CA-based company strengthens its mitral valve portfolio, it also faces a lawsuit from Abbott Laboratories over the Pascal system.
Ablative Solutions revealed data from the Peregrine Post-Market Study during the 2019 Cardiovascular Research Technologies meeting in Washington D.C. recently.